Cargando…

Iron-loaded deferiprone can support full hemoglobinization of cultured red blood cells

Iron, supplemented as iron-loaded transferrin (holotransferrin), is an essential nutrient in mammalian cell cultures, particularly for erythroid cultures. The high cost of human transferrin represents a challenge for large scale production of red blood cells (RBCs) and for cell therapies in general....

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallego-Murillo, Joan Sebastián, Yağcı, Nurcan, Pinho, Eduardo Machado, Wahl, Sebastian Aljoscha, van den Akker, Emile, von Lindern, Marieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147612/ https://www.ncbi.nlm.nih.gov/pubmed/37117329 http://dx.doi.org/10.1038/s41598-023-32706-1

Ejemplares similares

Expansion and differentiation of ex vivo cultured erythroblasts in scalable stirred bioreactors
por: Gallego‐Murillo, Joan Sebastián, et al.
Publicado: (2022)

Hemoglobin switching in mice carrying the Klf1Nan variant
por: Korporaal, Anne, et al.
Publicado: (2020)

Novel variants in Krueppel like factor 1 that cause persistence of fetal hemoglobin in In(Lu) individuals
por: Eernstman, Jesse, et al.
Publicado: (2021)

Mechanical Stress Induces Ca(2+)-Dependent Signal Transduction in Erythroblasts and Modulates Erythropoiesis
por: Aglialoro, Francesca, et al.
Publicado: (2021)

Quantum chemical analysis of the deferiprone–iron binding reaction
por: Wiwanitkit, Viroj
Publicado: (2006)

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
por: Kim, Choon-Mee, et al.
Publicado: (2009)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

The Shape Shifting Story of Reticulocyte Maturation
por: Ovchynnikova, Elina, et al.
Publicado: (2018)

CD14+ monocytes repress gamma globin expression at early stages of erythropoiesis
por: Heshusius, Steven, et al.
Publicado: (2021)

Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients
por: Won, Sung Chul, et al.
Publicado: (2010)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
por: Makis, Alexandros, et al.
Publicado: (2013)

Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone
por: Timoshnikov, Viktor A., et al.
Publicado: (2020)

The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia
por: Kontoghiorghes, George J., et al.
Publicado: (2020)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression
por: Uzungil, Volkan, et al.
Publicado: (2022)

Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE
por: Tran, Ngan Thi, et al.
Publicado: (2022)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Salmonella Typhimurium and Pseudomonas aeruginosa Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives
por: Ammendola, Serena, et al.
Publicado: (2021)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

S277: IPSC DISEASE MODELS TO STUDY AND TREAT DIAMOND-BLACKFAN ANEMIA SYNDROME (DBAS)
por: Clark, Chantal, et al.
Publicado: (2023)

Glutaraldehyde – A Subtle Tool in the Investigation of Healthy and Pathologic Red Blood Cells
por: Abay, Asena, et al.
Publicado: (2019)

Csde1 binds transcripts involved in protein homeostasis and controls their expression in an erythroid cell line
por: Moore, Kat S., et al.
Publicado: (2018)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
por: Olivieri, Nancy F., et al.
Publicado: (2019)

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
Publicado: (2019)

Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone
por: Wang, Chong, et al.
Publicado: (2023)

Strap associates with Csde1 and affects expression of select Csde1-bound transcripts
por: Moore, Kat S., et al.
Publicado: (2018)

Effects of iron supplementation on red blood cell hemoglobin content in pregnancy
por: Schoorl, Margreet, et al.
Publicado: (2012)

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review
por: Caro, J Jaime, et al.
Publicado: (2002)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation
por: Carboni, Eleonora, et al.
Publicado: (2017)

Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy
por: Romano, Nicola, et al.
Publicado: (2022)

Deferiprone−Resveratrol Hybrid, an Iron-Chelating Compound, Acts as an Antimalarial and Hepatoprotective Agent in Plasmodium berghei-Infected Mice
por: Chuljerm, Hataichanok, et al.
Publicado: (2022)

Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment
por: Goncalves, Sergio, et al.
Publicado: (2008)

Deferiprone‐induced agranulocytosis: 20 years of clinical observations
por: Tricta, Fernando, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fvlss7diup219un9qtildtmepc